Genmab A/S (GMAB) on Decifer

Decifer ranks GMAB number 55 of 265 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 9% and it turns most of its profit into real cash.
• Revenue is expected to grow about 17% a year, profits are expected to grow 45%, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Revenue growing 18 percent a year and profits expected to grow 48 percent are capped by no worldview role despite momentum of 20 out of 35.

The current read

The evidence on GMAB lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full GMAB research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.